Comparative Pharmacology
Head-to-head clinical analysis: PROLIXIN DECANOATE versus SPARINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROLIXIN DECANOATE versus SPARINE.
PROLIXIN DECANOATE vs SPARINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluphenazine decanoate is a long-acting phenothiazine antipsychotic that blocks dopamine D1 and D2 receptors in the brain, particularly in the mesolimbic and mesocortical pathways, with higher affinity for D2 receptors. It also exhibits alpha-adrenergic blocking and anticholinergic activity.
Phenothiazine antipsychotic; blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors; also blocks alpha-adrenergic receptors, and has anticholinergic and antihistaminergic effects.
Fluphenazine decanoate initial dose 12.5-25 mg IM or SC every 1-4 weeks; maintenance dose 12.5-50 mg every 2-4 weeks.
Promazine hydrochloride: 25-50 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 300 mg/day. Alternatively, oral: 25-200 mg every 4-6 hours; maximum 1000 mg/day. Route and frequency depend on indication and patient response.
None Documented
None Documented
Terminal elimination half-life approximately 14 days (range 6-25 days) after intramuscular injection, reflecting slow release from the oily depot; allows for every 2-4 week dosing.
Terminal elimination half-life: 10-20 hours; clinical context: allows once or twice daily dosing; extended in elderly and hepatic impairment
Renal (approximately 50% as conjugated metabolites, <1% unchanged) and fecal (approximately 30%, primarily via bile).
Primarily renal (70-80% as metabolites, less than 1% unchanged); biliary/fecal (15-30%)
Category C
Category C
Antipsychotic
Antipsychotic